Hyundai Bioscience Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Hyundai Bioscience.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Personal Products earnings growth	9.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Hyundai Bioscience Co., Ltd.'s (KOSDAQ:048410) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors

Dec 05

Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher

Jan 03

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

Nov 29

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hyundai Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A048410 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	15,818	-10,440	2,975	5,060	N/A
6/30/2024	17,323	-7,291	-3,324	-3,194	N/A
3/31/2024	11,369	-11,217	-11,611	-11,510	N/A
12/31/2023	9,481	-14,499	-6,596	-6,008	N/A
9/30/2023	10,061	-17,559	-11,011	-10,168	N/A
6/30/2023	10,481	-12,224	-16,241	-15,056	N/A
3/31/2023	8,671	-15,770	-17,324	-15,557	N/A
12/31/2022	7,852	-15,807	-18,087	-16,544	N/A
9/30/2022	8,659	-18,174	-18,694	-17,200	N/A
6/30/2022	8,739	-24,122	-14,118	-12,836	N/A
3/31/2022	9,631	-19,713	-7,763	-3,909	N/A
12/31/2021	9,241	-20,051	-4,300	-538	N/A
9/30/2021	8,696	-13,115	-11,833	16,881	N/A
6/30/2021	9,193	-10,845	-12,709	15,850	N/A
3/31/2021	10,285	-9,553	-15,123	10,271	N/A
12/31/2020	12,511	-8,260	-17,702	7,502	N/A
9/30/2020	18,275	-1,691	-3,559	-2,541	N/A
6/30/2020	21,868	-559	-2,033	-984	N/A
3/31/2020	26,434	-71	-4,061	-1,016	N/A
12/31/2019	30,086	1,569	-3,887	9,179	N/A
9/30/2019	31,481	4,116	-4,107	12,677	N/A
6/30/2019	32,363	4,039	-525	16,271	N/A
3/31/2019	32,926	3,855	-1,059	13,733	N/A
12/31/2018	31,236	3,108	227	5,005	N/A
9/30/2018	33,569	2,208	1,077	1,222	N/A
6/30/2018	34,127	2,100	N/A	-3,192	N/A
3/31/2018	32,164	2,044	N/A	-4,902	N/A
12/31/2017	31,970	1,218	N/A	-3,696	N/A
9/30/2017	31,398	-6,244	N/A	-5,755	N/A
6/30/2017	31,790	-8,992	N/A	-5,085	N/A
3/31/2017	32,316	-9,329	N/A	777	N/A
12/31/2016	36,101	-8,070	N/A	-4,338	N/A
9/30/2016	33,497	-2,934	N/A	-2,738	N/A
6/30/2016	32,630	131	N/A	-1,280	N/A
3/31/2016	38,621	692	N/A	-2,644	N/A
12/31/2015	40,675	711	N/A	87	N/A
9/30/2015	41,067	1,242	N/A	-2,765	N/A
6/30/2015	40,609	501	N/A	-524	N/A
3/31/2015	33,182	-613	N/A	-2,973	N/A
12/31/2014	28,913	-1,323	N/A	-303	N/A
9/30/2014	27,058	-4,498	N/A	-3,497	N/A
6/30/2014	25,218	-6,735	N/A	-8,791	N/A
3/31/2014	24,750	-8,500	N/A	-7,040	N/A
12/31/2013	25,538	-9,499	N/A	-9,178	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A048410's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A048410's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A048410's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A048410's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A048410's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A048410's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 11:07
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hyundai Bioscience Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Hyundai Bioscience Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Hyundai Bioscience Co., Ltd.'s (KOSDAQ:048410) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors

Is Hyundai Bioscience (KOSDAQ:048410) A Risky Investment?

Hyundai Bioscience USA Signs an MOU with the University of California San Diego to Conduct an Investigator-Initiated Trial to Evaluate the Efficacy of Xafty

New major risk - Financial data availability

Hyundai Bioscience Co., Ltd. to Conduct Phase 3 Clinical Trial for High-Risk Group of COVID-19 Patients with the Goal of Emergency Use Authorization

Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 3 billion in funding

Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060).

Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer

Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060) for KRW 31 billion.

Full year 2023 earnings released: ₩365 loss per share (vs ₩402 loss in FY 2022)

New major risk - Share price stability

Vector Inc. (TSE:6058) completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410)

Vector Inc. (TSE:6058) completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410)

New major risk - Share price stability

Full year 2022 earnings released: ₩402 loss per share (vs ₩543 loss in FY 2021)

Less than half of directors are independent

Vector Inc. (TSE:6058) agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410) for KRW 13.7 billion.

Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA

Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials

Less than half of directors are independent

Hyundai Bioscience Co., Ltd. Announces Oral Antiviral Drug from Korea May Be A Problem Solver for Covid-19

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

New 90-day high: ₩37,100

Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?

Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher

Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19

New 90-day high: ₩13,650

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

New 90-day low: ₩10,150

New 90-day low: ₩10,800

Hyundai Bioscience Co., Ltd. announced that it has received KRW 32 billion in funding from a group of investors

Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 32 billion in funding from a group of investors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources